Comparison between stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF with GnRH antagonist protocol

References

• European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone.Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril 2002;78:520–8.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Holmes J,Jacobs HS. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis. Fertil Steril 2000;73:338–43.
   PubMed Web of Science ®Google Scholar
• Hompes PG, Broekmans FJ, Hoozemans DA, Schats R. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril 2008;89:1685–93.
   PubMed Web of Science ®Google Scholar
• Kilani Z, Dakkak A, Ghunaim S, et al. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod 2003;18:1194–9.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Abou-Setta AM, Aboulghar MA, et al. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online 2008;16:81–8.
   PubMed Web of Science ®Google Scholar
• Coomarasamy A, Afnan M, Cheema D, et al. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 2008;23:310–15.
   PubMed Web of Science ®Google Scholar
• van Wely M, Kwan I, Burt AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review. Hum Reprod Update 2012;18:111. doi: 10.1093/humupd/dmr048.
   PubMed Web of Science ®Google Scholar
• Filicori M, Cognigni GE, Pocognoli P, et al. Current concepts and novel applications of LH activity in ovarian stimulation. Trends Endocrinol Metab 2003;14:267–73.
   PubMed Web of Science ®Google Scholar
• Filicori M, Fazleabas AT, Huhtaniemi I, et al. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril 2005;84:275–84.
   PubMed Web of Science ®Google Scholar
• Platteau P, Andersen AN, Balen A, et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod 2006;21:1798–804.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Bu Z, Dai W, et al. Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis. Reprod Biol Endocrinol 2014;12:109. DOI: 10.1186/1477-7827-12-109.
   PubMed Web of Science ®Google Scholar
• Vuong TN, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged >/=35 years: a randomized controlled trial. Hum Reprod 2015;30:1188–95.
   PubMed Web of Science ®Google Scholar
• Lehert P, Schertz JC, Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol 2010;8:112.
   PubMed Web of Science ®Google Scholar
• Marrs R, Meldrum D, Muasher S, et al. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004;8:175–82.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online 2004;8:635–43.
   PubMed Web of Science ®Google Scholar
• Bosch E, Labarta E, Crespo J, et al. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril 2011;95:1031–6.
   PubMed Web of Science ®Google Scholar
• Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod 2006;21:3217–27.
   PubMed Web of Science ®Google Scholar
• Platteau P, Smitz J, Albano C, et al. Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril 2004;81:1401–4.
   PubMed Web of Science ®Google Scholar
• Bosch E, Vidal C, Labarta E, et al. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists – a randomized study. Hum Reprod 2008;23:2346–51.
   PubMed Web of Science ®Google Scholar
• Devroey P, Pellicer A, Nyboe Andersen A, Arce JC. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril 2012;97:561–71.
   PubMed Web of Science ®Google Scholar
• Arce JC, La Marca A, Mirner Klein B, et al. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013;99:1644–53.
   PubMed Web of Science ®Google Scholar
• Sibug RM, Datson N, Tijssen AM, et al. Effects of urinary and recombinant gonadotrophins on gene expression profiles during the murine peri-implantation period. Hum Reprod 2007;22:75–82.
   PubMed Web of Science ®Google Scholar
• Grøndahl ML, Borup R, Lee YB, et al. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. Fertil Steril 2009;91:1820–30.
   PubMed Web of Science ®Google Scholar
• Segers I, Adriaenssens T, Wathlet S, Smitz J. Gene expression differences induced by equimolar low doses of LH or hCG in combination with FSH in cultured mouse antral follicles. J Endocrinol 2012;215:269–80.
   PubMed Web of Science ®Google Scholar
• Wex J, Abou-Setta AM. Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization/intracytoplasmic sperm-injection cycles in Sweden. Clinicoecon Outcomes Res 2013;5:381–97.
   PubMedGoogle Scholar